PPCB Propanc Biopharma, Inc.
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertake research activities for the POP1 Program and the University of Granada to develop a synthetic recombinant version of PRP. Propanc Biopharma, Inc. was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. The company was incorporated in 2007 and is based in Camberwell, Australia.…
Industry Peers
BiotechnologyKey Statistics
About Propanc Biopharma (NASDAQ: PPCB)
›
Propanc Biopharma (NASDAQ: PPCB) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 2 employees.
The shares were at 1.941 USD on 13 November 2026, down 99.1% over 52 weeks. Its 52-week range is 1.630 USD to 315.00 USD: the price is 99.4% below the high and 19.1% above the low.
Its market capitalisation is 2.01M USD.
Propanc Biopharma reports return on equity of -200.6% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 322.89K USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health.